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A large number of drugs and an increasing number of environmental agents reportedly result in the
appearance of a number of autoantibodies and in many instances in the appearance of a range of
autoimmune clinical syndromes. The major disorders so recognized have marked resemblances to
the autoimmune disease systemic lupus erythematosus. The commonly used term is drug-induced
lupus; a better term is drug-related lupus. There is considerable interest at the present time in an
increasing number of environmental agents. There have been two epidemics in recent years-one
in Spain to a contaminant of rapeseed oil and one in the United States to a contaminant of
L-tryptophan that caused an eosinophilic myositis. It is important for physicians and others involved
in health care to recognize the potential associations of these diseases of unknown cause or
causes. Key words: autoimmunity, clinical features, drugs, environmental agents, laboratory
changes, mechanisms. - Environ Health Perspect 107(suppl 5):709-711 (1999).
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The cause or causes of the nearly 100
autoimmune disorders have in most cases not
been specifically defined, although much
information is available on mechanisms. First
observations on a possible relationship to
medications were made in 1945 when an
association was noted between a lupuslike
syndrome in a patient receiving sulfadiazine.
There were many subsequent reports impli-
cating sulfonamides and penicillin, again
with systemic lupuslike features. In 1953,
hydralazine given in the treatment ofhyper-
tension was also reported to be related to a
lupuslike syndrome. These observations by
Morrow et al. (1) were really the first sub-
stantially documented observations; the ear-
lier observations were on case reports, thus
leaving open the possibility that these could
have been cases ofidiopathic systemic lupus.
The drug procainamide, which is used for
the treatment ofcardiac arrhythmias (2), has
the best documented association with drug-
related lupus (DRL) syndromes. The anti-
convulsant drugs were first associated with
such presentations in 1957 (3). Since that
time, at least 70 pharmacologic and other
agents have been associated with DRL syn-
dromes. These include antiarrhythmic, anti-
hypertensive, antipsychotic, antithyroid,
antirheumatic, antibiotics, and more
recently, various biologic agents.
Table 1 lists the drugs currently associ-
ated with lupus syndromes. In recent years,
there has been an increasing number ofasso-
ciations with potential environmental factors.
Clinically, many of these associated syn-
dromes reflect other types of autoimmune
disorders similar to polymyositis, sclero-
derma/systemic sclerosis, various vasculiti-
dies, and other clinical syndromes that do
not necessarily fit under the known disease
headings. We have known for many years
that certain chemicals may initiate clinical
syndromes such as acute hemolytic anemias.
Earlier and current observations relate vari-
ous heavy metal exposures to autoimmune
phenomenon and, in some cases, to very
specific renal disorders.
Because of these observations, there is
considerable thought about unknown envi-
ronmental agents as a potential cause or
causes for many autoimmune diseases and
perhaps even for other disorders. However,
there is no evidence that such agents cause
idiopathic systemic lupus erythematosus
(SLE). This article reviews the clinical simi-
larities or differences against the more stan-
dard idiopathic autoimmune diseases and the
mechanisms involved and concludes with
speculations on the future.
Clinical Features
Most information contrasting idiopathic SLE
with drug-related syndromes is from the
studies and reports documenting where these
reactions to a specific medication occur.
Clinical features related to possible environ-
mental factors are reviewed as the second part
ofthis section. One problem is that although
the American College of Rheumatology
(ACR) has defined classification criteria for
SLE (4) and for 11 other rheumatic diseases,
criteria for drugs and environmental factors
have not been determined and are still evolv-
ing. The Environmental Study Group ofthe
ACR has proposed a set ofcriteria to be pub-
lished in the near future.
First it should be noted that with DRL
most of the observed reactions occur in the
elderly population because of the higher
incidence of diseases for which the specific
drugs are prescribed. Reactions to the anti-
convulsant drugs are seen more often in
younger age groups. DRL also occurs only
slightly more frequently in females than in
males, and at least in the United States, it
appears more frequently in Caucasians than
in African Americans. Idiopathic SLE
occurs mostly in younger women and in the
United States in a high proportion of
African Americans.
The disease symptoms are somewhat
milder, and as the potential association with a
drug or medication is noted, the symptoms
can often be aborted when the offending drug
is stopped. Clinically, the skin, renal, and
neurologic features ofSLE are relatively rare
in DRL. Table 2 lists the frequency ofclinical
and laboratory features in the two types of
lupus disorders.
Laboratory Changes
Clearly, at least until now, the "ticket of
admission" to diagnosis has been a positive
antinuclear antibody (ANA). The laboratory
profiles ofidiopathic SLE and DRL are listed
in Table 2. The ANA staining pattern is usu-
ally the diffuse type, and antibodies to single-
stranded DNA (ssDNA) as opposed to
double-stranded DNA (dsDNA) are seen
with DRL. Antibodies to histones are seen
very frequentlywith DRL and there has been
considerable study ofthese antibodies to dif-
ferent histone proteins. With different drugs,
there appears to be a broad array ofautoanti-
genic epitopes to the individual histone and
histone complexes. Recent work suggests that
a switch from IgM to IgG isotype may pre-
cede the development of lupuslike syn-
dromes, particularly in patients taking
procainamide (5). It should also be noted
that antiphospholipid antibodies and lupus
anticoagulants occur in DRL. They have
been found with a long list ofdrugs and are
frequently ofthe IgM subclass. Other anti-
bodies that have been reported with different
drugs include lymphocytotoxic, antineu-
trophilic, anticytoplasmic antibodies, and
antibodies to both hydralazine and
procainamide metabolites.
It is appropriate to make some specific
comments relative to some drugs and biologic
agents. Minocycline hydrochloride, a
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Table 1. Drugs associated with DRL.
Drugs definitively associated with DRL.a
Chlorpromazine
Hydralazine
Isoniazid
Methyidopa
Minocycline
Procainamide
Quinidine
Otherdrugsassociated with DRL and currently in use.b
Acebutolol Methimazole
Acecainide Metroprolol
Allopurinol Metrizamide
Aminoglutethimide Minocycline
Amoproxan Minoxidil
Anthiomaline Nalidixic acid
Antitumor necrosis Nitrofurantoin
factor-a Oxyphenisatin
Atenolol Oxyprenolol
Benoxaprofen p-Amino salicyclic
Captopril acid
Carbamazepine Penicillamine
Chlorprothixene Penicillin
Chlorthalidone Perazine
Cimetidine Perphenazine
Cinnarazine Pheneizene
Clonidine Phenytoin
Danazol Prazosin
Diclofenac Primidone
1,2-Dimethyl-3-hydroxy Prindolol
pyride-4-1 Promethazine
Diphenylhydantoin Propafenone
Disopyriamide Prophythiouracil
Enalapril Propranolol
Estrogens Pyrathiazine
Ethosuximide Pyrithoxine
Ethylphenacemide Quinine
Gold salts Reserpine
Griseofulvin Spironolactone
Guanoxan Streptomycin
Ibuprofen Sulfadimethoxine
Interferon-a Sulfamethoxy
Interferon-y Sulfasalazine
lnterleukin-2 Sulindac
Labetalol Tetracyclines
Leuprolide acetate Tetrazine
Levadopa Thioridazide
Levomeprazone Timolol eyedrops
Lithium carbonate Tolazamide
Lovastatin Tolmetin
Mephenytoin Trimethadione
DRL, drug-related lupus. &Substantial observations and studies.
bA few are single case reports but the majority represent good
clinical observations.
semisynthetic tetracycline, has long been used
for the treatment ofthe skin disorder acne
vulgaris. It was first noted to be related with
DRL in 1992 (6) and to the present time, an
additional 76 cases have been published.
Most ofthese cases appear to occur in young
women, perhaps because they are most often
being treated for acne.
A polyarthralgia or polyarthritis affecting
the small joints, rather similar to rheumatoid
arthritis, is a common feature. The duration
oftherapy has ranged from a fewweeks to 10
years. Another feature ofDRL is that not all
ofthe patients have a positive ANA; antibod-
ies to dsDNA, phospholipids and to
p-ANCA antibodies have been reported (7).
Table 2. Frequency of clinical and laboratoryfeatures in
idiopathic SLE and DRL.
Features Idiopathic SLE DRL
Constitutional 40-85 40-50
Arthralgias/arthritis 75-95 80-95
Myalgias 40-80 35-57
Rash 50-70 0-30
Lymphadenopathy 23-67 <15
Pleurisy 42-60 0-52
Pleural effusion 16-20 0-33
Pulmonary infiltrates 0-10 5-40
Pericarditis 20-30 0-18
Hepatomegaly 10-31 0-25
Splenomegaly 9-46 0-20
Renal involvement 50 0-13
(hydralazine)
Neurologic involvement 25-70 0-2
Anemia 30-90 0-53
Leukopenia 35-66 0-33
Thrombocytopenia 20-50 0-10
Positive Coombs 18-30 0-23
Elevated ESR 50-75 60-93
Antinuclear antibodies >95 100
Antibodies to histones 50-70 >95
Antibodies to dsDNA 50 <5
Anti-Sm antibodies 25 < 5
Hypocomplementemia 40-65 0-25
Rheumatoid factor 25 20-40
Abbreviations: anti-Sm, anti-Smith; DRL, drug-related lupus;
dsDNA, double-stranded DNA; ESR, erythrocyte sedimentation
rate; SLE, systemic lupuserythematosus.
Table 3. Environmental factors reported to be associated
with the development of autoantibodies and lupuslike
syndromes.
Hydrazines
Tartrazine
Hairdyes
Chemicals used in computer manufacturing
? Trichloroethylene
? Industrial emissions and hazardous wastes
Silica (quartz)
Paraffin/silicone
Mercury
Cadmium
Gold
t-Canavanine
Rapeseed oil, toxic oil syndrome
L-Tryptophan, eosinophilia myalgia syndrome
Biologic Agents
Biologic agents are being used increasingly for
the treatment ofmalignancies, infections, and
many autoimmune diseases. Such agents
indude many cytokines such as interferon-a,
-[, and -,y, interleukin-2, and more recently,
antitumor necrosis factor-a used in the treat-
ment of rheumatoid arthritis. Many anti-
bodies have been reported including positive
ANAs and anti-DNA antibodies but also
clinical features ofautoimmune thyroid dis-
ease, autoimmune hemolytic anemia, and
thrombocytopenia, lupuslike syndromes, per-
nicious anemia, and vasculitis with the use of
these antibodies (8).
Environmental Agents
Since the acceptance that various drugs and
medications can induce autoimmune phe-
nomena and disease states, greater interest has
focused on the potential ofenvironmental
agents to do the same. Early reports discussed
the possibility ofhydrazines as an inciting fac-
tor (9) and in recent years the list has grown.
This area was given great impetus by two epi-
demics-a toxic oil syndrome in Spain due to
a contaminant in rapeseed oil (10) and, more
recently, in the United States, theeosinophilic
myalgia syndrome related to a possible con-
taminant in L-tryptophan (11). The list of
reported associations is given in Table 3. A
dietary factor, L-canavanine, is included. This
is a common amino acid in alfalfa seeds and
sprouts and a relationship to a lupuslike syn-
drome has been described in the United States
(12). The concern is that with the increasing
use ofhealth food products, other such associ-
ations may occur. It is important for physi-
cians to be alert to thesepossibilities.
Confirmation ofobservations relating to
manyoftheseenvironmental factors bythe use
ofprospective controlled studies is urgently
needed. Forexample, thepotentialrelationship
ofthe onset oflupus to hair dyes has not been
confirmed by more recent studies (13).
Similarly, observations by Vojdani et al. (14)
on immune dysregulation in workers exposed
to different chemicals in computer manufac-
turing plants have not yet been confirmed.
Various reported increased prevalence ofanti-
nuclear antibodies and lupuslike syndromes in
communities exposed to well water contami-
nated bytrichloroethylene andother chemicals
in Arizona, North Georgia, and Texas await
furtherstudyandconfirmation.
The relationship oflupus syndromes and
scleroderma to silica has been confirmed by
studies in miners in Silesia (15). Data pre-
sented at this meeting have shown an associa-
tion of scleroderma in South Carolina to
solvent-oriented hobbies (16).
There is little need to provide any details
here about the controversy relating to injec-
tion or implantation ofparaffin and silicone
in breast augmentation procedures. Where
large-scale studies have been performed, defin-
itive associations have not been shown.
Interpretation is made even more difficult by
the wide range of symptoms reported; the
general term "siliconosis" has been invoked.
A detailed study ofthe two large con-
firmed environmental outbreaks is recom-
mended to the reader. The first ofthese was
the outbreak in Spain in 1981 in over 35,000
people related to the ingestion ofdenatured
rapeseed oil (10). Again, what is striking is the
verylonglist ofnonspecific symptoms-fever,
malaise, lung involvement, muscle/joint
involvement, and the eventual appearance of
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sclerodermalike disease, lupuslike disease,
peripheral neuropathies, and Sj6gren-like syn-
dromes. Long-term follow-up has shown the
persistence ofdisease in about 10% ofthose
originally affected. Similarly, the eosinophilia
myalgia syndrome first described by Edison
et al. (11) in 1989 had a similar range of
symptoms and was characterized by a marked
increase in peripheral blood eosinophils and
muscle disease confirmed by muscle biopsy.
On follow-up, many ofthese patients devel-
oped a scleroderma-like condition, lung
involvement, and sensory neuropathies, again
similar to that in the Spanish outbreak. ANAs
and antihistone antibodies were present, but
antibodies to different nuclear and cytoplas-
micantigenswere negative.
It is of note that a number of other
compounds can also give rise to an
eosinophilic myalgia or myositis syndrome.
These include Tranilast (a mast cell stabi-
lizer), sulfisoxazole, penicillamine, simetha-
dine, phenytoin and alcohol.
Heavy Metals
It is well known that chronic exposure to a
number ofmetals such as mercury, gold, and
cadmium can induce autoantibodies and clin-
ically an immune complex-mediated glo-
merulonephritis. Most ofthese observations
have been in animals, although there are now
some reports in humans. The latter have
occurred mainly in patients exposed to mer-
cury through the use of skin-lightening
creams (17). The immune deposition of
immunoglobulins has been noted in patients
receivingchronic administration ofgold.
Possible Mechanisms
andthe Future
The mechanisms bywhich these drugs and/or
their metabolites, the chemicals and their
breakdown products, and the other environ-
mental factors and their various structures are
as diverse as the entire immune system itself.
Literally hundreds ofpapers have examined
the drugs and other factors listed in this arti-
cle and about every conceivable effect has
been noted. It is not possible to define a spe-
cific role or pathway that would result in the
varied immunologic and clinical syndromes
seen. For drugs such as hydralazine and pro-
cainamide, the specific metabolites that react
with specific immune cells have been well
demonstrated (18,19). Other proposed
mechanisms for a number ofthe compounds
include the possibility ofcross-reactive anti-
gens, interference with various tolerance
mechanisms, potential alteration ofDNA by
the drugs or their metabolites, and the role of
the genetics ofthe various metabolic path-
ways ofthe compounds, in particular the
P450 enzyme system. Studies ofthe actual
drugstructures foranycommonalityhave not
been very productive. Basically, the various
drugs often fall under three different struc-
tural groups: hydrazines, aromatic amines,
and phenols. Studies to date ofthe various
environmental factors again have not revealed
anymajorcommonality.
Another factor that has to be considered
in humans and experimental animals is the
possible inciting or potentiating effect of
infectious agents. Myxoviruses, retroviruses,
measles, rubella, parainfluenza, Epstein-Barr,
Type C oncarnoviruses, and Type C retro-
viruses could all play a role and must be con-
sidered when looking at mechanisms of
cross-reactive antigens (20). Among the bac-
teria under consideration are streptococcal
cell wall products, lipopolysaccharides, and
adjuvant components.
The genetics ofthe immune system in
autoimmune diseases and phenomena is
increasingly complex. Itwould appear that for
any one compound or environmental agent,
genetic factors may differ. There is also the
added complication ofthe genetics ofthe host
response as manifested in the expression of
different disease states. However complicated,
such studies should continue and be sup-
ported, as can be seen from theexample ofthe
specific genetic association ofHLA-DP.B1
glutamate in beryllium-exposed workers (21).
The National Research Council established a
program in 1991 to define biologic markers
in immunotoxicology. This and many other
aspects ofthe National Toxicology Program
should be strongly supported and is a
recommendation ofthis conference.
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